Health
IMV Provides Updates On COVID-19 Vaccine Program – Press Release – Digital Journal
“We are advancing DPX-COVID-19 on the strength of its novel mechanism of action and potential for rapid scale-up manufacturing. We greatly appreciate the recogn…
DARTMOUTH, Nova Scotia–(Business Wire)–IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today provides updates on its vaccine candidate, DPX-COVID-19, for the prevention of infection caused by the novel coronavirus SARS-COV-2.
We are advancing DPX-COVID-19 on the strength of its novel mechanism of action and potential for rapid scale-up manufacturing. We greatly appreciate …
-
Noosa News21 hours agoPilot left with life-threatening burns to his body as plane crashes to ground in Raglan, Queensland
-
Noosa News15 hours agoTeenage girl killed in house fire in Lawnton, Queensland as police probe potential e-bike link
-
Noosa News22 hours agoWhen will my HECS debt be cut? Millions of Australians wake to 20 per cent cut
-
Noosa News17 hours agoBrisbane film festival’s program highlights and locations